Andrea P. Myers - Concepedia

Author

Andrea P. Myers

The University of Texas MD Anderson Cancer Center

Also Known As

A. Myers, Andrea Myers, Andrea P Myers, Andrea P. Myers, Andrea Pomrehn Myers

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Novartis (Switzerland)Massachusetts General Hospital Cornell University

About

Andrea P. Myers is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	257
2	Cell Biology	4	4	172
3	Biochemistry	1	1	11
4	Cellular Physiology	1	1	59
5	Hepatology	1	1	27

Andrea P. Myers

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
High Frequency of <i>PIK3R1</i> and <i>PIK3R2</i> Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability Lydia W.T. Cheung, Bryan T. Hennessy, Jie Li, Cancer Discovery	2011	467
Oncogenic mutations in cervical cancer Alexi A. Wright, Brooke E. Howitt, Andrea P. Myers, Cancer	2013	268
Essential and opposing roles of zebrafish β-catenins in the formation of dorsal axial structures and neurectoderm Gianfranco Bellipanni, Máté Varga, S. Maegawa, Development	2006	150
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang, Journal of Experimental & Clinical Cancer Research	2022	71
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial Edward B. Garon, Shun Lü, Yasushi Goto, Journal of Clinical Oncology	2023	67
Characterization of Mouse <i>Rsk4</i> as an Inhibitor of Fibroblast Growth Factor-RAS-Extracellular Signal-Regulated Kinase Signaling Andrea P. Myers, Laura Corson, Janet Rossant, Molecular and Cellular Biology Rtk InhibitionSignal TransductionDevelopmental BiologySignaling PathwayReceptor Tyrosine Kinase	2004	59
A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations Courtney D. DiNardo, Aaron D. Schimmer, Karen Yee, Blood	2016	59
A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition Hailing Cheng, Pixu Liu, Fan Zhang, Cancer Research Tumor BiologyDual Pi3k/mtor InhibitorSignaling PathwayEndocrine-related CancerMedicine	2013	58
Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer Andrea P. Myers, Panagiotis A. Konstantinopoulos, William T. Barry, International Journal of Cancer	2019	58
PTEN loss is a context‐dependent outcome determinant in obese and non‐obese endometrioid endometrial cancer patients Shannon N. Westin, Zhenlin Ju, Russell R. Broaddus, Molecular Oncology	2015	52

Page 1